Theranos Retracts Submission of Zika Blood Test to FDABy
Testing firm didn’t use patient-safety protocol, Journal says
Controversial lab startup appealing proposed FDA sanctions
Theranos Inc. withdrew its submission for emergency clearance of a diagnostic blood test for the Zika virus after regulators found problems with how the blood-testing startup gathered patient data.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.